At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 1,053 enrolled
Drug / intervention
Fingolimod +1 moredrug
Likely dose
Fingolimod 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 6-month, Randomized, Active Comparator, Open-label, Multi-Center Study to Evaluate Patient OutComes, Safety and Tolerability of Fingolimod (FTY720) 0.5 mg/Day in Patients With Relapsing Forms of Multiple Sclerosis Who Are Candidates for MS Therapy Change From Previous Disease Modifying Therapy (EPOC)
In Brief
A Phase 4 clinical trial evaluating Fingolimod and Standard MS DMTs for Relapsing Forms of Multiple Sclerosis. Completed, enrolled 1,053 participants across 149 sites in 3 countries.
Detailed Summary
The purpose of this study is to evaluate the change in patient-reported outcomes, physician assessment of a change as well as safety and tolerability in patients with Relapsing Forms of Multiple Sclerosis on previous Disease Modifying Therapy (DMT) who are randomized to one of two treatment arms: fingolimod vs. standard of care DMT.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRelapsing Forms of Multiple Sclerosis
CountriesCanada, Puerto Rico, United States
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2010
First PostedOct 2010
Primary CompletionAug 2012
TodayJul 2026
First PostedOct 7, 2010
Enrollment StartAug 1, 2010
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.7 years ago
Interventions
Fingolimoddrug
0.5 mg/day oral capsule
Standard MS DMTsdrug